Literature DB >> 25722452

Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement.

Pauline Huet1, Samuel Burg2, Dominique Le Guludec2, Fabien Hyafil2, Irène Buvat3.   

Abstract

UNLABELLED: PET with (18)F-FDG shows promise for the evaluation of metabolic activities in atherosclerotic plaques. Although recommendations regarding the acquisition and measurement protocols to be used for (18)F-FDG PET imaging of atherosclerosis inflammation have been published, there is no consensus regarding the most appropriate protocols, and the image reconstruction approach has been especially overlooked. Given the small size of the targeted lesions, the reconstruction and measurement methods might strongly affect the results. We determined the differences in results due to the protocol variability and identified means of increasing the measurement reliability.
METHODS: An extensive literature search was performed to characterize the variability in atherosclerosis imaging and quantification protocols. Highly realistic simulations of atherosclerotic carotid lesions based on real patient data were designed to determine how the acquisition and processing protocol parameters affected the measured values.
RESULTS: In 49 articles, we identified 53 different acquisition protocols, 51 reconstruction protocols, and 46 quantification methods to characterize atherosclerotic lesions from (18)F-FDG PET images. The most important parameters affecting the measurement accuracy were the number of iterations used for reconstruction and the postfiltering applied to the reconstructed images, which could together make the measured standardized uptake values (SUVs) vary by a factor greater than 3. Image sampling, acquisition duration, and metrics used for the measurements also affected the results to a lesser extent (SUV varying by a factor of 1.3 at most). For an acceptable SUV variability, the lowest bias in SUV was observed using an 8-min acquisition per bed position; ordered-subset expectation maximization reconstruction with at least 120 maximum likelihood expectation maximization equivalent iterations, including a point spread function model using a 1 mm(3) voxel size; and no postfiltering. Because of the partial-volume effect, measurement bias remained greater than 60%. The use and limitations of the target-to-blood activity ratio metrics are also presented and discussed.
CONCLUSION: (18)F-FDG PET protocol harmonization is needed in atherosclerosis imaging. Optimized protocols can significantly reduce the measurement errors in wall activity estimates, but PET systems with higher spatial resolution and advanced partial-volume corrections will be required to accurately assess plaque inflammation from (18)F-FDG PET.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-FDG PET; atherosclerosis; partial-volume effect; vascular lesions

Mesh:

Substances:

Year:  2015        PMID: 25722452     DOI: 10.2967/jnumed.114.142596

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  46 in total

1.  High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined (18)F-FDG PET/MR imaging.

Authors:  Fabien Hyafil; Andreas Schindler; Dominik Sepp; Tilman Obenhuber; Anna Bayer-Karpinska; Tobias Boeckh-Behrens; Sabine Höhn; Marcus Hacker; Stephan G Nekolla; Axel Rominger; Martin Dichgans; Markus Schwaiger; Tobias Saam; Holger Poppert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-03       Impact factor: 9.236

2.  Feasibility of (18)F-Fluorodeoxyglucose radiotracer dose reduction in simultaneous carotid PET/MR imaging.

Authors:  Mootaz Eldib; Jason Bini; Olivier Lairez; David D Faul; Niels Oesingmann; Zahi A Fayad; Venkatesh Mani
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

3.  Nuclear imaging for patients with a suspicion of infective endocarditis: Be part of the team!

Authors:  Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2015-12-29       Impact factor: 5.952

4.  Quantification of FDG uptake in patients with a suspicion of prosthetic valve endocarditis: Part of the problem or part of the solution?

Authors:  Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2017-07-24       Impact factor: 5.952

5.  Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?

Authors:  Gang Cheng; Thomas J Werner; Andrew Newberg; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

6.  Adjustment of vascular 2-deoxy-2-[18F]fluoro-D-glucose uptake values over time through a modeling approach.

Authors:  Pavlos P Kafouris; Iosif P Koutagiar; Alexandros T Georgakopoulos; Nikoletta K Pianou; Marinos G Metaxas; George M Spyrou; Constantinos D Anagnostopoulos
Journal:  Int J Cardiovasc Imaging       Date:  2019-01-31       Impact factor: 2.357

7.  Can FDG-PET imaging play a role in guiding indications to endovascular treatments in patients presenting acute aortic syndromes?

Authors:  Michael Soussan; Fabien Hyafil
Journal:  J Nucl Cardiol       Date:  2017-10-16       Impact factor: 5.952

8.  Technical considerations for quantification of 18F-FDG uptake in carotid atherosclerosis.

Authors:  Sina Tavakoli
Journal:  J Nucl Cardiol       Date:  2017-11-17       Impact factor: 5.952

9.  Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients?

Authors:  Nidaa Mikail; Mathieu Sinigaglia; Fabien Hyafil
Journal:  J Nucl Cardiol       Date:  2018-03-08       Impact factor: 5.952

10.  Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation.

Authors:  Minyoung Oh; Cheol Whan Lee; Hyo Sang Lee; Mineok Chang; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Dae Hyuk Moon; Seong-Wook Park; Seung-Jung Park
Journal:  Clin Cardiol       Date:  2016-07-26       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.